No connection

Search Results

CPHI vs JNJ

CPHI
China Pharma Holdings, Inc.
BEARISH
Price
$0.63
Market Cap
$25.5M
Sector
Healthcare
AI Confidence
95%
JNJ
Johnson & Johnson
NEUTRAL
Price
$237.96
Market Cap
$573.46B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
CPHI
--
JNJ
21.55
Forward P/E
CPHI
--
JNJ
18.9
P/B Ratio
CPHI
0.43
JNJ
7.03
P/S Ratio
CPHI
6.15
JNJ
6.09
EV/EBITDA
CPHI
-18.34
JNJ
17.81

Profitability

Gross Margin
CPHI
-3.18%
JNJ
68.08%
Operating Margin
CPHI
-97.86%
JNJ
23.97%
Profit Margin
CPHI
-76.92%
JNJ
28.46%
ROE
CPHI
-20.91%
JNJ
35.03%
ROA
CPHI
-8.41%
JNJ
8.68%

Growth

Revenue Growth
CPHI
8.1%
JNJ
9.1%
Earnings Growth
CPHI
--
JNJ
48.6%

Financial Health

Debt/Equity
CPHI
0.17
JNJ
0.6
Current Ratio
CPHI
0.32
JNJ
1.03
Quick Ratio
CPHI
0.09
JNJ
0.69

Dividends

Dividend Yield
CPHI
--
JNJ
2.19%
Payout Ratio
CPHI
0.0%
JNJ
46.6%

AI Verdict

CPHI BEARISH

CPHI exhibits severe financial distress, anchored by a weak Piotroski F-Score of 2/9 and a critical liquidity crisis. The company is operating with a negative gross margin (-3.18%), meaning it loses money on every product sold before operating expenses are even considered. With a current ratio of 0.32 and a quick ratio of 0.09, the firm lacks the liquid assets to cover its short-term obligations. This fundamental collapse is reflected in a catastrophic 5-year price decline of 99.8%.

Strengths
Low Debt/Equity ratio (0.17) suggests limited long-term leverage
Modest year-over-year revenue growth of 8.10%
Trading at a discount to book value (P/B 0.43)
Risks
Critical liquidity risk with a Current Ratio of 0.32
Negative gross margins indicate a non-viable core business model
Severe profitability collapse (Operating Margin -97.86%)
JNJ NEUTRAL

JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.

Strengths
Exceptional Return on Equity (ROE) of 35.03%
Strong profit margins (28.46%) and gross margins (68.08%)
Consistent earnings beat track record over 25 quarters
Risks
Weak Piotroski F-Score (3/9) indicating declining fundamental health
Bearish insider activity with $58.35M in net sales and zero buys
Low liquidity indicated by a Quick Ratio of 0.69

Compare Another Pair

CPHI vs JNJ: Head-to-Head Comparison

This page compares China Pharma Holdings, Inc. (CPHI) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile